AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 111 min read$IRTC

Turakhia Minang sold $884K of IRTC

Turakhia Minang (CHIEF MED/SCI OFCR EVP ADVTECH) sold 7,093 shares of iRhythm Holdings, Inc. (IRTC) at $124.65 ($0.88M total) on 2026-08-10.

Original reporting
SEC EDGAR · Turakhia Minang
Published Aug 11, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IRTC
Neutral
medium confidence
Mentioned
$IRTC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRTCNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale size, price, and post-transaction holdings of an executive officer.

02

Market read

Traders may note insider selling as a sentiment datapoint, but the filing alone does not provide a new fundamental driver.

03

What to watch

No 10b5-1 plan is stated, but the article also lacks context on total holdings, prior sales cadence, tax events, or whether the sale was part of a broader planned schedule.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-11, transaction dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for iRhythm Holdings, Inc. (IRTC).

Company-level read

Ticker impact

$IRTCNeutralMedium confidence
Context

Form 4 shows Turakhia Minang, iRhythm’s EVP AdvTech, sold 7,093 shares on 2026-08-10 for about $884,151 at $124.6512.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than earnings or guidance-driven.

Evidence & confidence

The filing is primary-source and time-stamped, but insider sales are common and the article provides no accompanying operational or financial change.

Market effects

Sector

Minimal; insider sale does not change sector fundamentals or regulatory outlook based on the provided text.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be routine liquidity management and does not necessarily signal reduced confidence, especially without any accompanying negative company-specific news.

Key entities

  • issuer
    iRhythm Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Turakhia Minang

    Chief Med/SCI Officer, EVP AdvTech, reported the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IRTC insider trading history →

Related articles

OCT 5
$IRTCMedAI 8/10

iRhythm completes acquisition of VitalConnect

iRhythm (IRTC) completed its acquisition of VitalConnect for $237.5M in cash and up to 423,334 shares. The deal includes a $10M working capital funding. VitalConnect's cardiac monitoring platform offers 30-day patient monitoring and 11 physiological parameters. iRhythm expects enhanced revenue growth from 2027, maintaining a 15% adjusted EBITDA margin target. Updated 2026 guidance will be provided in November 2026.

investing.com2 min
OCT 5
$IRTCMedAI 9/10

Transaction Detail The purchase consideration consisted of $237.5 million in cash, subject to customary adjustments, funded from iRhythm's balance sheet and…

iRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Regulation FD Disclosure. iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care  Combination broadens iRhythm’s cardiac monitoring portfolio, advances its multi-vitals strategy and expands iRhythm’s addressable mark

SEC EDGAR 8-K2 min
OCT 5
$IRTCHighAI 9/10

iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

iRhythm (IRTC) completed its acquisition of VitalConnect, a leader in wearable biosensor and ambulatory cardiac monitoring technology. The $237.5M cash deal, plus up to 423,334 shares, is expected to expand iRhythm's cardiac monitoring portfolio, accelerate growth, and preserve its 15% adjusted EBITDA margin target for 2027. The combined entity aims to serve more patients and customers across various care settings.

globenewswire.com3 min
SEP 22
$IRTCMedAI 8/10

IRhythm Holdings, Inc., a Delaware corporation, iRhythm Technologies, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company…

iRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01. Regulation FD Disclosure. As previously announced, on August 5, 2026, iRhythm Holdings, Inc., a Delaware corporation (the “Company”), iRhythm Technologies, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (“Acquirer”), Project Vessel Mer

SEC EDGAR 8-K1 min